Bioconjugates labeled with alpha- and beta-particle emitting radionuclides as potential radiopharmaceuticals in Targeted Radionuclide Therapy.
2019/34/E/ST4/00080
Keywords
Descriptors
- ST4_009: Chemia biologiczna
- ST4_018: Chemia jądrowa i radiacyjna
- NZ7_014: Farmacja, farmakoterapia, farmakologia
Panel
ST4 – Chemistry: physical chemistry/chemical physics, theoretical chemistry, analytical chemistry, inorganic chemistry, organic chemistry, method development
Host institution
Instytut Chemii i Techniki Jądrowej
Voivodeship: mazowieckie
Principal investigator (from the host institution)
Number of co-investigators in the project: 5
Call
SONATA BIS 9 – announced on 2019-06-17
- Amount awarded
- 1 652 200 PLN
- Project start date
- 2020-04-06
- Project end date
- 2026-10-05
- Project duration
- 78 months (the same as in the proposal)
- Project status
- Pending project
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (1)
-
Preclinical evaluation of 225Ac-labeled single-domain antibody for the treatment of HERpos cancer
- Authors:
- Rodak M, Dekempeneer Y, Wojewódzka M, Caveliers V, Covens P, Miller BW, Sevenois MB, Bruchertseifer F, Morgenstern A, Lahoutte T, D'Huyvetter M, Pruszyński M
- Academic press:
- Molecular Cancer Therapeutics (year: 2022, volume: 21, pages: 1835–1845), Publisher: American Association for Cancer Research
- Status:
- Published
- DOI:
- 10.1158/1535-7163.MCT-21-0220 – link to the publication